Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer

被引:870
作者
Hartmann, LC
Schaid, DJ
Woods, JE
Crotty, TP
Myers, JL
Arnold, PG
Petty, PM
Sellers, TA
Johnson, JL
McDonnell, SK
Frost, MH
Jenkins, RB
机构
[1] Mayo Clin & Mayo Fdn, Dept Oncol, Div Med Oncol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Div Biostat, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Div Plast & Reconstruct Surg, Rochester, MN 55905 USA
[4] Mayo Clin & Mayo Fdn, Div Clin Epidemiol, Rochester, MN 55905 USA
[5] Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[6] St Vincents Hosp, Dept Pathol, Dublin 4, Ireland
关键词
D O I
10.1056/NEJM199901143400201
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Options for women at high risk for breast cancer include surveillance, chemoprevention, and prophylactic mastectomy. The data on the outcomes for surveillance and prophylactic mastectomy are incomplete. Methods We conducted a retrospective study of all women with a family history of breast cancer who underwent bilateral prophylactic mastectomy at the Mayo Clinic between 1960 and 1993. The women were divided into two groups - high risk and moderate risk - on the basis of family history. A control study of the sisters of the high-risk probands and the Gall model were used to predict the number of breast cancers expected in these two groups in the absence of prophylactic mastectomy. Results We identified 639 women with a family history of breast cancer who had undergone bilateral prophylactic mastectomy: 214 at high risk and 425 at moderate risk. The median length of follow-up was 14 years. The median age at prophylactic mastectomy was 42 years. According to the Gall model, 37.4 breast cancers were expected in the moderate-risk group; 4 breast cancers occurred (reduction in risk, 89.5 percent; P<0.001). We compared the numbers of breast cancers among the 214 high-risk probands with the numbers among their 403 sisters who had not undergone prophylactic mastectomy. Of these sisters, 38.7 percent (156) had been given a diagnosis of breast cancer (115 cases were diagnosed before the respective proband's prophylactic mastectomy, 38 were diagnosed afterward, and the time of the diagnosis was unknown in 3 cases). By contrast, breast cancer was diagnosed in 1.4 percent (3 of 214) of the probands. Thus, prophylactic mastectomy was associated with a reduction in the incidence of breast cancer of at least 90 percent. Conclusions In women with a high risk of breast cancer on the basis of family history, prophylactic mastectomy can significantly reduce the incidence of breast cancer. (N Engl J Med 1999;340:77-84.) (C) 1999, Massachusetts Medical Society.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 40 条
  • [1] *AM SOC PLAST REC, 1994, PROPH MAST
  • [2] [Anonymous], 1980, DHHS PUBL
  • [3] Graphs to estimate an individualized risk of breast cancer
    Benichou, J
    Gail, MH
    Mulvihill, JJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 103 - 110
  • [4] Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history
    Berry, DA
    Parmigiani, G
    Sanchez, J
    Schildkraut, J
    Winer, E
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) : 227 - 238
  • [5] THE WOMAN AT INCREASED RISK FOR BREAST-CANCER - EVALUATION AND MANAGEMENT STRATEGIES
    BILIMORIA, MM
    MORROW, M
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 1995, 45 (05) : 263 - 278
  • [6] VALIDATION OF A BREAST-CANCER RISK ASSESSMENT MODEL IN WOMEN WITH A POSITIVE FAMILY HISTORY
    BONDY, ML
    LUSTBADER, ED
    HALABI, S
    ROSS, E
    VOGEL, VG
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (08) : 620 - 625
  • [7] Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2
    Burke, W
    Daly, M
    Garber, J
    Botkin, J
    Kahn, MJE
    Lynch, P
    McTierman, A
    Offit, K
    Perlman, J
    Petersen, G
    Thomson, E
    Varricchio, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12): : 997 - 1003
  • [8] CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO
  • [9] 2-5
  • [10] COHEN MM, 1994, AM J HUM GENET, V55, pR1